Please login to the form below

Not currently logged in
Email:
Password:

Patent cliff losses set to cost pharma $65bn by 2019

Lilly, AZ and Otsuka to be hit hard, says GlobalData

Pharma spendingPharma firms should brace themselves for an estimated $65bn drop in sales by 2019 due to patent expiries on several leading drugs, according a new report.

Research and consulting company GlobalData says a significant proportion of losses will come from the central nervous system (CNS) treatment sector, with Otsuka, Eli Lilly and AstraZeneca (AZ) expected to be hit hard.

For Lilly and AZ it continues their sales declines in the area as their flagship brands continue to suffer.

GlobalData analyst Adam Dion said: “AZ, CNS segment has been bleeding sales as a result of the company losing its patent on Seroquel (quetiapine), a treatment for bipolar disorder. GlobalData estimates AZ's share to have been around 9% in 2010, which has now fallen to only 3% in 2013.

“Eli Lilly's market share declines from 14.3% in 2010 to 11.2% in 2013, primarily thanks to decreasing sales of Zyprexa (olanzapine). Zyprexa sales have plummeted from over $5bn to $1,2bn over the same period as a result of the drug losing its US patent exclusivity in 2011.”

Dion added that, although Otsuka's anti-psychotic drug Abilify (aripiprazole) - co-owned with Bristol-Myers Squibb - was the sales leader in CNS, bringing in $9.5bn in 2013, the future of the drug is not so positive with its US patent expiration in 2015, leading to a potential loss of $6.2bn by 2019.

However, industry-wide the picture may be more positive. Research from IMS Health published last month predicted global medicines spending would grow by $305-335bn in the five years to the end of 2018. 

Article by
Kirstie Pickering

16th December 2014

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....